Work

A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors.

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.15_suppl.3004

Authors: A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos, C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4242522656

Cites:

Cited by: 35

Related to: 10